Experts have co-developed a 5-item questionnaire to assess reliance. Click below to view the Blue Reliever Reliance test.
Asthma is due to chronic airway inflammation4. Although SABA also commonly known as the "Blue Reliever Inhaler" provides quick relief of symptoms which last for 3-6 hours5. over-reliance (e.g. patients use SABA three or more times a week) is associated with increased risk of exacerbations.1
Meanwhile, using three or more canisters per year is associated with two times likelihood of hospitalisation.2
Some patients see their blue reliever inhaler as the most important part of their asthma treatment without recognizing that SABA monotherapy will worsen asthma inflammation6.
This short test is designed to assess what your patients think of their SABA inhaler and if they may be relying on it too much
Take the short test now to get first-hand experience of the feedback patients will receive based on their responses
This is not medical advice for patients to stop taking their medicine. The programme is designed to support conversations between healthcare professionals and patients.
IPCRG VERSION 2.0.
1. NPJ Prim Care Respir Med. 2014;24:14009.
2. Global Initiative for Asthma (GINA). Available at: https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf (last accessed December 2019).
3. Psychology & Health. 1999;14(1):1–24.
4. Asthma: Definition. Chronic Respiratory Diseases. World Health Organization. Available at: "https://www.who.int/respiratory/asthma/definition/en/.
5. Billington CK, Penn RB and Hall IP. Handb Exp Pharmacol. 2017 ; 237: 23–40. doi:10.1007/164_2016_64.
6. Edwards MR, et al. J Biol Chem. 2007;282:15366-15375;
This site is intended for healthcare professionals